Telomir Pharmaceuticals Reports Board and Executive Compensation Changes
Ticker: TELO · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1971532
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Telomir Pharma shakes up board, adjusts exec pay.
AI Summary
Telomir Pharmaceuticals, Inc. announced on December 17, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, alongside updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial priorities that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- December 17, 2025 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but does not name the individual.
Who was elected to the board of directors?
The filing indicates the election of a new director, but does not name the individual.
What is the exact date of the earliest reported event?
The earliest event reported is dated December 17, 2025.
What is the company's state of incorporation?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
What are the key items reported in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 14.1 · Accepted 2025-12-19 20:00:25
Key Financial Figures
- $400,000 — proved a short-term incentive payout of $400,000, reflecting Company performance across
- $150,000 — proved a contingent milestone payout of $150,000, which will become payable upon future
- $500,000 — tee and Board approved a base salary of $500,000, effective January 1, 2026, consistent
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-25-028620.txt ( ) — 210KB
- telo-20251217.xsd (EX-101.SCH) — 3KB
- telo-20251217_lab.xml (EX-101.LAB) — 34KB
- telo-20251217_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: December 19, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer